NDATOPICALPATCH
Approved
Feb 2018
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
5/8 — Partial
ZTLIDO (lidocaine) by PharmaIN is clinical pharmacology mechanism of action: lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. First approved in 2018.
Drug data last refreshed 1h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZTLIDO is a topical lidocaine 5% patch approved in 2018 for localized pain relief via transdermal delivery. It stabilizes neuronal membranes to inhibit ionic fluxes required for pain signal initiation and conduction. The patch provides rapid onset (3–5 minutes) and is indicated for patients requiring topical anesthesia at accessible skin sites.
$0.051BPart D
Peak4.8 years to LOEProduct is at peak commercial maturity with $51M annual Part D spending and nearly 79K claims, supporting a stable mid-size brand team focused on market maintenance and payer relationships.
Mechanism of Action
CLINICAL PHARMACOLOGY Mechanism of action: Lidocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Onset of anesthesia: Lidocaine Ointment 5% effects local, topical anesthesia. The…
Worked on ZTLIDO at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.